Avelumab in Combination With Lorlatinib or Crizotinib in Patients With Previously Treated Advanced NSCLC: Phase 1b/2 Results From the JAVELIN Lung 101 Trial.

BJ, Solomon; I, Dagogo-Jack; SH, Lee; MJ, Boyer; SS, Ramalingam; E, Carcereny; E, Felip; JY, Han; T, Hida; BGM, Hughes; SW, Kim; M, Nishio; T, Seto; T, Okamoto; X, Zhang; JF, Martini; E, Wang; Beukelaer S, De; TM, Bauer

doi:10.1016/j.jtocrr.2024.100685

Public

Avelumab in Combination With Lorlatinib or Crizotinib in Patients With Previously Treated Advanced NSCLC: Phase 1b/2 Results From the JAVELIN Lung 101 Trial.

Shared by NobleBlocks on May 16, 2024 • 12:00 AM UTC

Authors:

Solomon BJ

Dagogo-Jack I

Lee SH

Abstract

<h4>Introduction</h4>The JAVELIN Lung 101 phase 1b/2 trial evaluated avelumab (immune checkpoint inhibitor) combined with lorlatinib or crizotinib (tyrosine kinase inhibitors) in <i>ALK</i>-positive or <i>ALK</i>-negative advanced NSCLC, respectively.<h4>Methods</h4>Starting doses of lorlatinib 100 ...

Subject

Crizotinib

Non–small Cell Lung Cancer

Avelumab

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!